Stage III Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Radiation Oncology

Background:

• Over 20% of non-small cell lung cancer (NSCLC) diagnoses are Stage III, indicating locoregionally advanced tumors.
• Local therapies (surgery, radiation) alone yield poor survival in Stage III NSCLC due to frequent distant metastases.
• Chemotherapy combinations with local treatments have been a focus for improving outcomes over the last two decades.

Purpose of the Study:

• To review the current understanding and treatment strategies for Stage III non-small cell lung cancer.
• To evaluate the role and selection criteria for surgical resection in locoregionally advanced NSCLC.
• To highlight the importance of systemic therapy in managing distant metastatic risk.

Main Methods:

• Literature review of studies on Stage III NSCLC treatment.
• Analysis of surgical outcomes and patient selection criteria.
• Evaluation of chemotherapy regimens combined with local therapies.

Main Results:

• Surgery selection criteria for Stage III NSCLC have been defined.
• Chemotherapy combined with local therapy is crucial for improving survival.
• Distant metastases remain the primary cause of mortality.

Conclusions:

• Stage III NSCLC requires multimodal treatment approaches.
• Optimizing the integration of chemotherapy, surgery, and radiation is key.
• Further research into systemic therapies is essential for reducing distant recurrence.